Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda
BACKGROUND: Both 1 month of daily (1HP) and 3 months of weekly (3HP) isoniazid-rifapentine are recommended as short-course regimens for TB prevention among people living with HIV (PLHIV). We aimed to assess acceptability and preferences for 1HP vs. 3HP among PLHIV. METHODS: In a cross-sectional surv...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
International Union Against Tuberculosis and Lung Disease (The Union)
2024-02-01
|
| Series: | IJTLD Open |
| Subjects: | |
| Online Access: | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000002/art00005 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592345583845376 |
|---|---|
| author | A. Musinguzi H. E. Aschmann J. L. Kadota J. Nakimuli F. Welishe J. Kakeeto C. Namale L. Akello A. Nakitende C. Berger A. Katamba J. Tumuhamye N. Kiwanuka D. W. Dowdy A. Cattamanchi F. C. Semitala |
| author_facet | A. Musinguzi H. E. Aschmann J. L. Kadota J. Nakimuli F. Welishe J. Kakeeto C. Namale L. Akello A. Nakitende C. Berger A. Katamba J. Tumuhamye N. Kiwanuka D. W. Dowdy A. Cattamanchi F. C. Semitala |
| author_sort | A. Musinguzi |
| collection | DOAJ |
| description | BACKGROUND: Both 1 month of daily (1HP) and 3 months of weekly (3HP) isoniazid-rifapentine are recommended as short-course regimens for TB prevention among people living with HIV (PLHIV). We aimed to assess acceptability and preferences for 1HP vs. 3HP among PLHIV. METHODS: In a cross-sectional survey among PLHIV at an HIV clinic in Kampala, Uganda, participants were randomly assigned to a hypothetical scenario of receiving 1HP or 3HP. Participants rated their level of perceived intention and confidence to complete treatment using a 0–10 Likert scale, and chose between 1HP and 3HP. RESULTS: Among 429 respondents (median age: 43 years, 71% female, median time on ART: 10 years), intention and confidence were rated high for both regimens. Intention to complete treatment was rated at least 7/10 by 92% (189/206 randomized to 1HP) and 93% (207/223 randomized to 3HP). Respectively 86% (178/206) and 93% (208/223) expressed high confidence to complete treatment. Overall, 81% (348/429) preferred 3HP over 1HP. CONCLUSIONS: Both 1HP and 3HP were highly acceptable regimens, with 3HP preferred by most PLHIV. Weekly, rather than daily, dosing appears preferable to shorter duration of treatment, which should inform scale-up and further development of short-course regimens for TB prevention. |
| format | Article |
| id | doaj-art-4aabf4b58b3e411dbf5bd338163d310f |
| institution | Kabale University |
| issn | 3005-7590 |
| language | English |
| publishDate | 2024-02-01 |
| publisher | International Union Against Tuberculosis and Lung Disease (The Union) |
| record_format | Article |
| series | IJTLD Open |
| spelling | doaj-art-4aabf4b58b3e411dbf5bd338163d310f2025-01-21T10:20:39ZengInternational Union Against Tuberculosis and Lung Disease (The Union)IJTLD Open3005-75902024-02-0112838910.5588/ijtldopen.23.02835Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in UgandaA. Musinguzi0H. E. Aschmann1J. L. Kadota2J. Nakimuli3F. Welishe4J. Kakeeto5C. Namale6L. Akello7A. Nakitende8C. Berger9A. Katamba10J. Tumuhamye11N. Kiwanuka12D. W. Dowdy13A. Cattamanchi14F. C. Semitala15Infectious Diseases Research Collaboration, Kampala,Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USADivision of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USAInfectious Diseases Research Collaboration, Kampala,Infectious Diseases Research Collaboration, Kampala,Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda;Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda;Infectious Diseases Research Collaboration, Kampala,Infectious Diseases Research Collaboration, Kampala,Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USAUganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda;School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda;School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda;Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda;Center for Tuberculosis, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA;Infectious Diseases Research Collaboration, Kampala,BACKGROUND: Both 1 month of daily (1HP) and 3 months of weekly (3HP) isoniazid-rifapentine are recommended as short-course regimens for TB prevention among people living with HIV (PLHIV). We aimed to assess acceptability and preferences for 1HP vs. 3HP among PLHIV. METHODS: In a cross-sectional survey among PLHIV at an HIV clinic in Kampala, Uganda, participants were randomly assigned to a hypothetical scenario of receiving 1HP or 3HP. Participants rated their level of perceived intention and confidence to complete treatment using a 0–10 Likert scale, and chose between 1HP and 3HP. RESULTS: Among 429 respondents (median age: 43 years, 71% female, median time on ART: 10 years), intention and confidence were rated high for both regimens. Intention to complete treatment was rated at least 7/10 by 92% (189/206 randomized to 1HP) and 93% (207/223 randomized to 3HP). Respectively 86% (178/206) and 93% (208/223) expressed high confidence to complete treatment. Overall, 81% (348/429) preferred 3HP over 1HP. CONCLUSIONS: Both 1HP and 3HP were highly acceptable regimens, with 3HP preferred by most PLHIV. Weekly, rather than daily, dosing appears preferable to shorter duration of treatment, which should inform scale-up and further development of short-course regimens for TB prevention.https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000002/art00005tuberculosis preventive treatmentacceptabilityvalueshuman immunodeficiency virus |
| spellingShingle | A. Musinguzi H. E. Aschmann J. L. Kadota J. Nakimuli F. Welishe J. Kakeeto C. Namale L. Akello A. Nakitende C. Berger A. Katamba J. Tumuhamye N. Kiwanuka D. W. Dowdy A. Cattamanchi F. C. Semitala Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda IJTLD Open tuberculosis preventive treatment acceptability values human immunodeficiency virus |
| title | Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda |
| title_full | Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda |
| title_fullStr | Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda |
| title_full_unstemmed | Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda |
| title_short | Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda |
| title_sort | preference for daily 1hp vs weekly 3hp isoniazid rifapentine among people living with hiv in uganda |
| topic | tuberculosis preventive treatment acceptability values human immunodeficiency virus |
| url | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000002/art00005 |
| work_keys_str_mv | AT amusinguzi preferencefordaily1hpvsweekly3hpisoniazidrifapentineamongpeoplelivingwithhivinuganda AT heaschmann preferencefordaily1hpvsweekly3hpisoniazidrifapentineamongpeoplelivingwithhivinuganda AT jlkadota preferencefordaily1hpvsweekly3hpisoniazidrifapentineamongpeoplelivingwithhivinuganda AT jnakimuli preferencefordaily1hpvsweekly3hpisoniazidrifapentineamongpeoplelivingwithhivinuganda AT fwelishe preferencefordaily1hpvsweekly3hpisoniazidrifapentineamongpeoplelivingwithhivinuganda AT jkakeeto preferencefordaily1hpvsweekly3hpisoniazidrifapentineamongpeoplelivingwithhivinuganda AT cnamale preferencefordaily1hpvsweekly3hpisoniazidrifapentineamongpeoplelivingwithhivinuganda AT lakello preferencefordaily1hpvsweekly3hpisoniazidrifapentineamongpeoplelivingwithhivinuganda AT anakitende preferencefordaily1hpvsweekly3hpisoniazidrifapentineamongpeoplelivingwithhivinuganda AT cberger preferencefordaily1hpvsweekly3hpisoniazidrifapentineamongpeoplelivingwithhivinuganda AT akatamba preferencefordaily1hpvsweekly3hpisoniazidrifapentineamongpeoplelivingwithhivinuganda AT jtumuhamye preferencefordaily1hpvsweekly3hpisoniazidrifapentineamongpeoplelivingwithhivinuganda AT nkiwanuka preferencefordaily1hpvsweekly3hpisoniazidrifapentineamongpeoplelivingwithhivinuganda AT dwdowdy preferencefordaily1hpvsweekly3hpisoniazidrifapentineamongpeoplelivingwithhivinuganda AT acattamanchi preferencefordaily1hpvsweekly3hpisoniazidrifapentineamongpeoplelivingwithhivinuganda AT fcsemitala preferencefordaily1hpvsweekly3hpisoniazidrifapentineamongpeoplelivingwithhivinuganda |